newsfilter
← Latest News
Business Wire·

BeOne Medicines' Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026

Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatment BRUKINSA plus sonrotoclax (ZS)